Tvardi Therapeutics (TVRD) posts wider losses and flags cash risk
Tvardi Therapeutics, Inc. is a clinical-stage biopharma developing oral STAT3 inhibitors TTI-101 (in Phase 1b/2 for hepatocellular carcinoma) and TTI-109 (next‑gen prodrug now through a positive Phase 1 healthy‑volunteer trial, with ulcerative colitis selected as its initial indication).
For the quarter ended June 30, 2026, Tvardi reported a net loss of $6.5 million and a six‑month net loss of $13.3 million, with no product revenue. Cash and cash equivalents were $15.8 million, total assets $17.5 million and accumulated deficit $123.7 million. Operating cash outflow for the first six months was $15.1 million.
Management states that these losses, limited cash and the need for significant additional funding raise substantial doubt about Tvardi’s ability to continue as a going concern. The company put in place a $200.0 million shelf registration and an at‑the‑market program, under which it has raised approximately $13.3 million gross through August 11, 2026.
Positive
- None.
Negative
- Substantial doubt about going concern: ongoing losses, $15.1 million operating cash outflow in six months, $15.8 million cash on hand and dependence on new financing lead management to conclude there is substantial doubt about the company’s ability to continue as a going concern.
Filing Explained
By August 11, common shares outstanding had risen to 13,338,943 after ATM sales, expanding the base over which existing holders’ ownership is measured.
After
The
The company reports 3,110,769 shares sold for approximately
The filing states that no further common stock will be sold under the original prospectus; subsequent issuance activity is therefore tied to the new supplement and its remaining stated capacity.
Key Figures
Key Terms
going concern financial
at-the-market offering financial
Investigational New Drug (IND) medical
STAT3 medical
Phase 1b/2 clinical trial medical
shelf registration statement regulatory
FAQ
What were Tvardi Therapeutics (TVRD) results for the quarter ended June 30, 2026?
What is Tvardi Therapeutics’ (TVRD) cash position and burn rate as of June 30, 2026?
Did Tvardi Therapeutics (TVRD) disclose a going-concern risk in this 10-Q?
What progress did Tvardi Therapeutics (TVRD) report on its TTI-101 and TTI-109 programs?
How is Tvardi Therapeutics (TVRD) planning to finance its operations going forward?
How many Tvardi Therapeutics (TVRD) shares are outstanding after recent ATM sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
FOR THE QUARTERLY PERIOD ENDED
OR
COMMISSION FILE NUMBER
(Exact name of registrant as specified in its charter)
| |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| |
| |
| |
(Address of registrant’s principal executive offices) | (Zip Code) |
| |
Registrant’s telephone number, including area code: (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ¨ |
☒ | Smaller reporting company | ||
| | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of August 11, 2026 was:
Table of Contents
TVARDI THERAPEUTICS, INC.
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026
` | | | | |
|---|---|---|---|---|
| | | | Page |
| | | | |
Part I | | Financial Information | | 3 |
| | | | |
Item 1. | | Financial Statements (Unaudited): | | 3 |
| | | | |
| | Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 | | 3 |
| | | | |
| | Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the Three and Six Months Ended June 30, 2026 and 2025 | | 4 |
| | | | |
| | Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Three and Six Months Ended June 30, 2026 and 2025 | | 5 |
| | | | |
| | Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 | | 6 |
| | | | |
| | Notes to Condensed Consolidated Financial Statements | | 7 |
| | | | |
Item 2. | | Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 21 |
| | | | |
Item 3. | | Quantitative and Qualitative Disclosures about Market Risk | | 36 |
| | | | |
Item 4. | | Controls and Procedures | | 37 |
| | | | |
Part II | | Other Information | | 39 |
| | | | |
Item 1. | | Legal Proceedings | | 39 |
| | | | |
Item 1A. | | Risk Factors | | 39 |
| | | | |
Item 2. | | Unregistered Sales of Equity Securities and Use of Proceeds | | 39 |
| | | | |
Item 3. | | Defaults Upon Senior Securities | | 39 |
| | | | |
Item 4. | | Mine Safety Disclosures | | 39 |
| | | | |
Item 5. | | Other Information | | 39 |
| | | | |
Item 6. | | Exhibits | | 39 |
| | | | |
| Signatures | | 42 |
Table of Contents
PART I —FINANCIAL INFORMATION
Item 1. Financial Statements
TVARDI THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands, except share and per share amounts)
| | | | | | | |
| | As of June 30, | | As of December 31, | | ||
| | 2026 | | 2025 | | ||
Assets | | | | | | | |
Current assets: |
| | |
| | | |
Cash and cash equivalents | | $ | | | $ | | |
Short-term investments | | | — | | | | |
Prepaid expenses and other current assets | |
| | |
| | |
Total current assets | |
| | |
| | |
Property and equipment, net | |
| | |
| | |
Intangible assets, net | |
| | |
| | |
Operating lease right-of-use assets | |
| | |
| | |
Other non-current assets | |
| | |
| | |
Total assets | | $ | | | $ | | |
| | | | | | | |
Liabilities and Stockholders' Equity | |
| | |
| | |
Current liabilities: | |
| | |
| | |
Accounts payable | | $ | | | $ | | |
Accrued expenses | |
| | |
| | |
Operating lease liabilities, current portion | |
| | |
| | |
Total current liabilities | |
| | |
| | |
Operating lease liabilities, net of current portion | |
| | |
| | |
Total liabilities | |
| | |
| | |
| | | | | | | |
Commitments and contingencies (Note 12) | |
| | |
| | |
| | | | | | | |
Stockholders' Equity: | |
| | |
| | |
Common stock, $ | |
| | |
| | |
Additional paid-in capital | |
| | |
| | |
Accumulated other comprehensive income | | | — | | | | |
Accumulated deficit | | | ( | |
| ( | |
Total stockholders' equity | |
| | |
| | |
Total liabilities and stockholders' equity | | $ | | | $ | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Table of Contents
TVARDI THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(Unaudited, amounts in thousands, except share and per share amounts)
| | | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | | ||||
Operating expenses: |
| | |
| | | | | |
| | | |
Research and development | | $ | | | $ | | | $ | | | $ | | |
General and administrative | |
| | |
| | |
| | |
| | |
Total operating expenses | |
| | |
| | |
| | |
| | |
Loss from operations | |
| ( | |
| ( | |
| ( | |
| ( | |
Interest income | |
| | |
| | |
| | |
| | |
Other income, net | |
| — | |
| | |
| — | |
| | |
Net (loss) income | | $ | ( | | $ | | | $ | ( | | $ | ( | |
| | | | | | | | | | | | | |
Net (loss) income per share attributable to common stockholders: | | | | | | | | | | | | | |
Basic | | $ | ( | | $ | | | $ | ( | | $ | ( | |
Diluted | | $ | ( | | $ | ( | | $ | ( | | $ | ( | |
Weighted-average common shares outstanding: | | | | | | | | | | | | | |
Basic | | | | | | | | | | | | | |
Diluted | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Comprehensive (loss) income: | | | | | | | | | | | | | |
Net (loss) income | | $ | ( | | $ | | | $ | ( | | $ | ( | |
Unrealized loss on short-term investments | |
| ( | |
| ( | |
| ( | |
| ( | |
Comprehensive (loss) income | | $ | ( | | $ | | | $ | ( | | $ | ( | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Table of Contents
TVARDI THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited, amounts in thousands, except share amounts)
| | | | | | | | | | | | | | | | | | | | | | | |
| | Redeemable | | | | | | | | | | | | | | Accumulated | | | | ||||
| | Convertible | | | | | | | | Additional | | | | | Other | | Total | ||||||
| | Preferred Stock | | | Common Stock | | Paid-In | | Accumulated | | Comprehensive | | Stockholders' | ||||||||||
| | Shares | | Amount | | | Shares | | Amount | | Capital | | Deficit | | Income (Loss) | | Equity (Deficit) | ||||||
Balances as of December 31, 2025 | | — | | $ | — | | | | | $ | | | $ | | | $ | ( | | $ | | | $ | |
Stock-based compensation |
| — |
| | — | |
| — |
| | — |
| | |
| | — |
| | — |
| | |
Unrealized loss on short-term investments |
| — |
| | — | |
| — |
| | — |
| | — |
| | — |
| | ( |
| | ( |
Net loss |
| — |
| | — | |
| — |
| | — |
| | — |
| | ( |
| | — |
| | ( |
Balances as of March 31, 2026 |
| — | | $ | — | |
| | | $ | | | $ | | | $ | ( | | $ | | | $ | |
Stock-based compensation | | — | | | — | | | — | | | — | | | | | | — | | | — | | | |
Unrealized loss on short-term investments | | — | | | — | | | — | | | — | | | — | | | — | | | ( | | | ( |
Net loss | | — | | | — | | | — | | | — | | | — | | | ( | | | — | | | ( |
Balances as of June 30, 2026 | | — | | $ | — | | | | | $ | | | $ | | | $ | ( | | $ | — | | $ | |
| | | | | | | | | | | | | | | | | | | | | | | |
Balances as of December 31, 2024 | | | | $ | | |
| | | $ | | | $ | | | $ | ( | | $ | — | | $ | ( |
Exercise of stock options | | — | | | — | | | | | | — | | | | | | — | | | — | | | |
Stock-based compensation | | — | | | — | | | — | | | — | | | | | | — | | | — | | | |
Unrealized gain on short-term investments | | — | | | — | | | — | | | — | | | — | | | — | | | | | | |
Net loss | | — | | | — | | | — | | | — | | | — | | | ( | | | — | | | ( |
Balances as of March 31, 2025 | | | | $ | | | | | | $ | | | $ | | | $ | ( | | $ | | | $ | ( |
Exercise of stock options | | — | | | — | | | | | | — | | | | | | — | | | — | | | |
Stock-based compensation | | — | | | — | | | — | | | — | | | | | | — | | | — | | | |
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger | | ( | | | ( | | | | | | | | | | | | — | | | — | | | |
Issuance of common stock upon the conversion of Convertible Notes | | — | | | — | | | | | | | | | | | | — | | | — | | | |
Issuance of common stock in connection with the Merger | | — | | | — | | | | | | | | | | | | — | | | — | | | |
Transaction costs in connection with the Merger | | — | | | — | | | — | | | — | | | ( | | | — | | | — | | | ( |
Unrealized loss on short-term investments | | — | | | — | | | — | | | — | | | — | | | — | | | ( | | | ( |
Net income | | — | | | — | | | — | | | — | | | — | | | | | | — | | | |
Balances as of June 30, 2025 |
| — | | $ | — | |
| | | $ | | | $ | | | $ | ( | | $ | ( | | $ | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Table of Contents
TVARDI THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)
| | | | | | | |
| | For the Six Months Ended June 30, | | ||||
| | 2026 | | 2025 | | ||
Cash flows from operating activities: |
| | |
| | | |
Net loss | | $ | ( | | $ | ( | |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | |
| | |
Depreciation and amortization expense | |
| | |
| | |
Stock-based compensation expense | |
| | |
| | |
Change in fair value of Convertible Notes | | | — | | | ( | |
Non-cash lease expense | |
| | |
| | |
Accretion of net discounts on short-term investments | |
| ( | |
| ( | |
Interest accrued on Convertible Notes | |
| — | |
| | |
Changes in operating assets and liabilities: | |
| | |
| | |
Prepaid expenses and other assets | |
| ( | |
| ( | |
Accounts payable and accrued expenses | |
| ( | |
| | |
Operating lease liabilities | |
| ( | |
| ( | |
Net cash used in operating activities | |
| ( | |
| ( | |
Cash flows from investing activities: | |
| | |
| | |
Purchases of short-term investments | |
| — | |
| ( | |
Maturities of short-term investments | |
| | |
| | |
Net cash provided by (used in) investing activities | |
| | |
| ( | |
Cash flows from financing activities: | |
| | |
| | |
Cash acquired in connection with the Merger | | | — | |
| | |
Payments for Merger transaction costs | | | — | |
| ( | |
Proceeds from exercise of stock options | |
| — | |
| | |
Net cash provided by financing activities | |
| — | |
| | |
Net decrease in cash and cash equivalents | |
| ( | |
| ( | |
Cash and cash equivalents - beginning of year | |
| | |
| | |
Cash and cash equivalents - end of period | | $ | | | $ | | |
| | | | | | | |
Non-cash investing and financing activities | |
| | |
| | |
Merger transaction costs included in accounts payable | | $ | — | | $ | | |
Conversion of redeemable convertible preferred stock to common stock | | $ | — | | $ | | |
Conversion of Convertible Notes to common stock | | $ | — | | $ | | |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Table of Contents
TVARDI THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1.Nature of the Business and Basis of Presentation
Tvardi Therapeutics, Inc. and its subsidiaries (Tvardi or the Company) is a Delaware corporation headquartered in Houston, Texas. The Company is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon its founders’ seminal work and deep understanding of the transcription factor STAT3, the Company has designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, the Company is developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. The Company’s pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is the Company’s first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance systemic drug delivery and improve tolerability. The Company submitted an Investigational New Drug (IND) application for TTI-109 in June 2025. In July 2026, the Company reported positive results from its Phase 1 clinical trial of TTI-109 in healthy volunteers evaluating safety, tolerability, pharmacokinetics and bioequivalence to TTI-101. Later in July 2026, the Company announced that it had selected ulcerative colitis (UC) as the initial disease indication for TTI-109.
Merger
On December 17, 2024, the Delaware corporation formerly known as Tvardi Therapeutics, Inc. (Legacy Tvardi) entered into an agreement and plan of merger and reorganization (the Merger Agreement) with Cara Therapeutics, Inc. (Cara), and CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of Cara (Merger Sub), pursuant to which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the merger as a wholly-owned subsidiary of Cara (such transaction, the Merger). Upon the closing of the Merger on April 15, 2025, Cara changed its corporate name to Tvardi Therapeutics, Inc. and Legacy Tvardi’s business continued as the business of the Company. Unless otherwise indicated or the context otherwise requires, references in these notes to condensed consolidated financial statements to “Tvardi” and “the Company” refer to the business and operations of Legacy Tvardi prior to the Merger and to Tvardi Therapeutics, Inc. and its consolidated subsidiaries following the Merger.
Risks and Uncertainties
The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, successful development of TTI-101 and TTI-109, the development of new technological innovations by competitors, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations and commercial success of TTI-101 and TTI-109. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.
Additionally, the Company is subject to risks and uncertainties as a result of global business, political and macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, uncertainty with respect to the federal budget and debt ceiling, as well as the potential for future potential government shutdowns related thereto, potential instability in the global banking system, cybersecurity events, the impact of war or military conflict, including regional conflicts around the world, and public health pandemics. The extent to which business, political and macroeconomic factors, including increasing financial market volatility and uncertainty, will impact the Company’s business will depend on future developments that are highly uncertain and cannot be predicted at this time.
7
Table of Contents
Liquidity and Going Concern
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
As of June 30, 2026, the Company had cash and cash equivalents of $
To date, the Company has no products approved for marketing and sale and it has not yet recorded any revenue from product sales. The Company’s ability to achieve profitability is dependent on its ability to successfully develop its compounds, conduct clinical trials, obtain regulatory approvals, and support commercialization activities for its product candidates. Any products developed will require approval of the U.S. Food and Drug Administration (FDA) or a foreign regulatory authority prior to commercial sale.
Significant additional funding is necessary to maintain current operations and to advance the Company’s research and development activities. The Company plans to seek additional funding through equity offerings or debt financings, credit or loan facilities, strategic alliances and licensing arrangements. The Company’s ability to access capital when and in the amount needed is not assured. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.
The accompanying condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.
Basis of Presentation
The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries as a result of the consummation of the Merger in April 2025. All intercompany balances and transactions have been eliminated.
The condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of June 30, 2026 and December 31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December 31, 2026.
Upon the closing of the Merger, the outstanding shares of common stock of Legacy Tvardi (including the shares of common stock issuable upon conversion of all shares of preferred stock of Legacy Tvardi prior to the Merger) were converted into shares of the Company’s common stock, based on an exchange ratio calculated in accordance with the Merger Agreement (the Exchange Ratio). The Exchange Ratio was retroactively applied to all outstanding common shares, redeemable convertible preferred stock, and stock options of Legacy Tvardi throughout the condensed consolidated financial statements and notes to condensed consolidated financial statements. Refer to Note 3 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December
8
Table of Contents
31, 2025, as filed with the Securities and Exchange Commission (SEC) on March 31, 2026, for additional information regarding the Merger.
2.Summary of Significant Accounting Policies
Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, prepaid and accrued research and development expenses, including those related to contract research organizations (CROs), contract development manufacturing organizations (CDMOs), and other third-party vendors, and the valuation of the Company’s common stock prior to the Merger, stock-based awards, and the fair value of Convertible Notes (as defined in Note 11, Net (Loss) Income Per Share), which converted to common stock upon close of the Merger. Changes in estimates are recorded in the period in which they become known.
Concentration of Credit Risk and of Significant Suppliers
The Company’s cash and cash equivalents represent potential concentrations of credit risk. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
The following table presents information about the Company’s significant suppliers:
| | | | | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | | | As of | | As of |
| | ||||
| | June 30, | | June 30, | | | June 30, | | December 31, |
| | ||||
| | 2026 | | 2025 | | 2026 | | 2025 | | | 2026 | | 2025 |
| |
|
| % of operating expenses |
| % of operating expenses | | | % of accounts payable | |
| ||||||
Vendor A |
| % | % | % | % | | % | % |
| ||||||
For the three and six months ended June 30, 2026 and 2025, no additional suppliers accounted for more than 10% of the Company’s operating expenses or accounts payable. The Company’s preclinical studies and clinical trials and testing could be adversely affected by a significant interruption in the supply chain from its significant suppliers.
Cash and Cash Equivalents
The Company considers all highly liquid investments, with an original maturity of three months or less, to be cash equivalents. Cash equivalents include amounts held in money market funds in the amount of $
The Company recorded interest income on its cash equivalents of $
Short-term Investments
The Company invests excess cash in short-term investments with high credit ratings. These securities consist primarily of U.S. Treasury Notes that are classified as “available-for-sale.” The Company classifies any investments as
9
Table of Contents
short-term if the maturity date is less than or equal to one year from the balance sheet date or as long-term if the maturity date is in excess of one year from the balance sheet date.
The Company’s short-term investments are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity (deficit). Realized gains and losses and declines in fair value due to credit-related factors are based on the specific identification method and would be included within the non-operating section of the condensed consolidated statements of operations and comprehensive (loss) income, as needed. The Company recorded interest income on short-term investments, inclusive of accretion of its discounts on its short-term investments, in an immaterial amount and $
At each balance sheet date, the Company assesses available-for-sale debt securities in an unrealized loss position to determine whether the unrealized loss or any potential credit losses should be recognized within the non-operating section of the condensed consolidated statement of operations and comprehensive (loss) income. The Company evaluates whether it intends to sell, or it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in the condensed consolidated statement of operations and comprehensive (loss) income accordingly, as needed. The portion that is not credit-related is treated in accordance with other unrealized losses as a component of accumulated other comprehensive income (loss) in stockholders’ equity (deficit). There have been
Comprehensive (Loss) Income
Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from nonowner sources, including unrealized gains and losses on short-term investments held as available-for-sale. For the three and six months ended June 30, 2026, comprehensive loss includes net loss and a net unrealized loss on short-term investments. For the three months ended June 30, 2025, comprehensive income includes net income and a net unrealized loss on short-term investments and for the six months ended June 30, 2025, comprehensive loss includes net loss and a net unrealized loss on short-term investments.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2025-11, Interim Reporting (Topic 270): Narrow Scope Improvements (or ASU 2025-11). The amendments in ASU 2025-11 are intended to improve the clarity and navigability of the interim reporting guidance in Topic 270 by clarifying its applicability, the types of interim reporting subject to the guidance, and the form and content of interim financial statements. The update also provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events occurring since the end of the most recent annual reporting period that have a material impact on the entity, without fundamentally changing or expanding existing disclosure requirements. This guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 for public business entities, with early adoption permitted. The Company is currently evaluating the provisions of this guidance and the potential impact on its condensed consolidated financial statements and disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (or ASU 2024-03). The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included in the statement of operations. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the provisions of this guidance and the potential impact on its condensed consolidated financial statements and disclosures.
10
Table of Contents
3.Fair Value Measurements
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):
| | | | | | | | | | | | |
| | Fair Value Measurements as of | ||||||||||
| | June 30, 2026 | ||||||||||
| | Level 1 | | Level 2 | | Level 3 | | Total | ||||
Financial assets: |
| | |
| | |
| | |
| | |
Cash equivalents: |
| | |
| | |
| | |
| | |
Money market funds | | $ | | | $ | — | | $ | — | | $ | |
Total financial assets | | $ | | | $ | — | | $ | — | | $ | |
| | | | | | | | | | | | |
| | Fair Value Measurements as of | ||||||||||
| | December 31, 2025 | ||||||||||
| | Level 1 | | Level 2 | | Level 3 | | Total | ||||
Financial assets: |
| | |
| | |
| | |
| | |
Cash equivalents: |
| | |
| | |
| | |
| | |
Money market funds | | $ | | | $ | — | | $ | — | | $ | |
Short-term investments | | | | | | | | | | | | |
U.S. Treasury Notes | | | | | | — | | | — | | | |
Total financial assets | | $ | | | $ | — | | $ | — | | $ | |
The Company did
The unrealized losses on the Company’s short-term investments for the three and six months ended June 30, 2026 and 2025 were not material.
4.Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following as of June 30, 2026 and December 31, 2025 (in thousands):
| | | | | | | |
| | As of June 30, | | As of December 31, | | ||
| | 2026 | | 2025 | | ||
Prepaid research and development expenses | | $ | | | $ | | |
Prepaid insurance | | | | | | | |
Other prepaid expenses | |
| | |
| | |
Total prepaid expenses and other current assets | | $ | | | $ | | |
5.Intangible Assets
Intangible assets consisted of the following as of June 30, 2026 and December 31, 2025 (in thousands):
| | | | | | | |
| | As of June 30, | | As of December 31, | | ||
| | 2026 | | 2025 | | ||
Licensed patent rights | | $ | | | $ | | |
Less: accumulated amortization | |
| ( | |
| ( | |
Total intangible assets, net | | $ | | | $ | | |
11
Table of Contents
As of June 30, 2026, the expected remaining amortization expense is as follows (in thousands):
| | | |
Year Ended December 31, | | Amount | |
2026 (remaining six months) | | $ | |
2027 |
| | |
2028 |
| | |
2029 |
| | |
2030 |
| | |
Thereafter |
| | |
Total | | $ | |
The Company recognized less than $
6.Accrued Expenses
Accrued expenses consisted of the following as of June 30, 2026 and December 31, 2025 (in thousands):
| | | | | | | |
| | As of June 30, | | As of December 31, | | ||
| | 2026 | | 2025 | | ||
Accrued research and development expenses | | $ | | | $ | | |
Accrued employee compensation and benefits | |
| | |
| | |
Accrued professional fees | |
| | |
| | |
Other accrued expenses | |
| | |
| | |
Total accrued expenses | | $ | | | $ | | |
7.Leases
The Company has
The components of lease costs, which are included within general and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive (loss) income were as follows (in thousands):
| | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Lease costs: |
| | |
| | |
| | |
| | |
Operating lease cost | | $ | | | $ | | | $ | | | $ | |
Variable lease cost | |
| | |
| | |
| | |
| |
Total lease costs | | $ | | | $ | | | $ | | | $ | |
Supplemental disclosure of cash flow information related to the lease were as follows (in thousands):
| | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Operating cash flows from operating leases | | $ | | | $ | | | $ | | | $ | |
12
Table of Contents
The weighted-average discount rate and remaining lease term were as follows:
| | | | | | | | | | |
| | For the Three Months Ended |
| | For the Six Months Ended |
| ||||
| | 2026 | | 2025 |
| | 2026 | | 2025 |
|
Weighted-average discount rate |
| | % | | % |
| | % | | % |
Weighted-average remaining lease term |
|
| |
|
| | ||||
As of June 30, 2026, the maturities of the Company’s operating lease liabilities were as follows (in thousands):
| | | |
Year Ended December 31, | | Amount | |
2026 (remaining six months) | | $ | |
2027 | |
| |
Total lease payments | |
| |
Less: imputed interest | |
| ( |
Present value of lease liabilities | |
| |
Less: operating lease liabilities, current portion | | $ | |
Operating lease liabilities, net of current portion | | $ | |
8.Stockholders’ Equity (Deficit)
Preferred Stock
As of June 30, 2026, the Company had
Common Stock
As of June 30, 2026 and December 31, 2025, the Company’s amended and restated certificate of incorporation authorized the issuance of
Each share of common stock entitles the holder to
Redeemable Convertible Preferred Stock
Prior to the Merger Agreement in April 2025, Legacy Tvardi had issued Series A preferred stock and Series B preferred stock (the Preferred Stock) and classified the Preferred Stock as temporary equity since the shares had redemption features that were not entirely within the control of Legacy Tvardi. Upon the closing of the Merger in April 2025, Legacy Tvardi’s Preferred Stock converted into
Shelf Registration and ATM Facility
On May 1, 2026, the Company filed a shelf registration statement on Form S-3 (the Registration Statement) which permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $
13
Table of Contents
the Registration Statement, including the ATM Facility. See Note 15, Subsequent Events, for information regarding issuances of securities after June 30, 2026.
9.Stock-based Compensation
2018 Equity Incentive Plan
Legacy Tvardi’s 2018 Stock Incentive Plan (the 2018 Plan) provided employees, consultants and advisors and non-employee members of the Board of Directors and its affiliates with the opportunity to receive grants of stock options, stock awards and equity awards. Since inception, Legacy Tvardi only issued stock options. The Company assumed, effective as of the closing of the Merger, the 2018 Plan, as well as the outstanding awards granted thereunder and the award agreements evidencing the grants of such awards, including any awards granted to the Company’s named executive officers, in each case subject to applicable adjustments in the manner set forth in the Merger Agreement to such awards. No further awards will be granted under the 2018 Plan following the Merger.
2025 Equity Incentive Plan
The Company’s 2025 Equity Incentive Plan (the 2025 Plan) became effective at the closing of the Merger. As of the effective time of the Merger, there were
Shares underlying any Awards that are forfeited, canceled, or reacquired by the Company prior to vesting, satisfied without the issuance of stock or otherwise terminated and shares that are withheld upon exercise of an option of settlement of an award to cover the exercise price or tax withholding shall be added back to the shares available for issuance under the 2025 Plan. As of June 30, 2026, the Company had
2025 Employee Stock Purchase Plan
The Company’s 2025 Employee Stock Purchase Plan (the 2025 ESPP) became effective at the closing of the Merger. As of the effective time of the Merger, there were
Fair Value Inputs
The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company historically had been a private company prior to the Merger and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so after the Merger until such time as it has adequate
14
Table of Contents
historical data regarding the volatility of its own publicly traded stock price. The expected option term is calculated based on the simplified method for awards with service-based conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.
The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted. For options granted during the three and six months ended June 30, 2026 and 2025, the Company’s closing stock price on the grant date was used.
| | | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended |
| ||||||||
| | June 30, | | June 30, |
| ||||||||
| | 2026 | | | 2025 | | 2026 | | 2025 |
| |||
Per share fair value of common stock | | $ | | | $ | | | $ | | | $ | | |
Expected volatility | |
| % | | % |
| % |
| % | ||||
Expected dividends | |
| — | % | | — | % |
| — | % |
| — | % |
Expected term (in years) | |
| | | | | |
| | ||||
Risk-free rate | |
| % | | | % |
| % |
| | % | ||
Stock Options
The Company granted
The weighted-average grant date fair value per share of options granted to non-employee members of the Company’s Board of Directors and a consultant during the three months ended June 30, 2026 was $
The following table summarizes option activity during the six months ended June 30, 2026:
| | | | | | | | | | |
| | | | Weighted- | | Weighted-Average | | | | |
| | Number of | | Average Exercise | | Remaining Contractual | | Intrinsic Value (In | ||
| | Options | | Price | | Term (In Years) | | Thousands) | ||
Outstanding as of January 1, 2026 |
| | | $ | |
| | $ | | |
Granted |
| | |
| |
| | |
| |
Outstanding as of June 30, 2026 |
| | | $ | |
| | $ | | |
Options exercisable as of June 30, 2026 |
| | | $ | |
| | $ | | |
Vested and expected to vest as of June 30, 2026 |
| | | $ | |
| | $ | | |
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock. There were
15
Table of Contents
The following table illustrates the classification of stock-based compensation in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):
| | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Research and development | | $ | | | $ | | | $ | | | $ | |
General and administrative | |
| | |
| | |
| | |
| |
Total stock-based compensation | | $ | | | $ | | | $ | | | $ | |
As of June 30, 2026, there was $
10.Income Taxes
For the three and six months ended June 30, 2026 and 2025, there was
11.Net (Loss) Income Per Share
Basic and diluted net (loss) income per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):
| | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Numerator: |
| | |
| | |
| | |
| | |
Net (loss) income for basic net (loss) income per share attributable to common stockholders | | $ | ( | | $ | | | $ | ( | | $ | ( |
Reversal of fair market value remeasurement net gain on Convertible Notes (1) | | | — | | | ( | | | — | | | ( |
Add back of interest expense from the Convertible Notes (1) | | | — | | | | | | — | | | |
Net loss for diluted net loss per share attributable to common stockholders | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
| | | | | | | | | | | | |
Denominator: | |
| | |
| | |
| | |
| |
Weighted-average common shares outstanding, basic | |
| | |
| | |
| | |
| |
Effect of potentially dilutive securities: | | | | | | | | | | | | |
Convertible Notes | | | — | | | | | | — | | | |
Weighted-average common shares outstanding, diluted | | | | | | | | | | | | |
| | | | | | | | | | | | |
Net (loss) income per share attributable to common stockholders: | | | | | | | | | | | | |
Basic | | $ | ( | | $ | | | $ | ( | | $ | ( |
Diluted | | $ | ( | | $ | ( | | $ | ( | | $ | ( |
________________________
16
Table of Contents
Upon the closing of the Merger in April 2025, the Convertible Notes converted into
For the three and six months ended June 30, 2026, the Company’s potentially dilutive securities include its stock options to purchase common stock. All of the Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2026, as the effect would be anti-dilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2026 is the same. For the three and six months ended June 30, 2025, the Company’s potentially dilutive securities included its stock options to purchase common stock, Preferred Stock, and Convertible Notes. The Company’s Convertible Notes had been included in the computation of diluted net loss per share for the three and six months ended June 30, 2025 as the effect was determined to be dilutive, while its stock options to purchase common stock and Preferred Stock were excluded from the diluted net loss per share calculation as the effect was determined to be anti-dilutive.
The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
| | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||
| | 2026 | | 2025 | | 2026 | | 2025 |
Stock options to purchase common stock |
| |
| |
| |
| |
12.Commitments and Contingencies
Legal Matters
The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the condensed consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of June 30, 2026 and December 31, 2025, the Company was not a party to any material legal proceedings or claims.
Contracts
The Company enters into contracts in the normal course of business with various third parties for preclinical research studies, clinical trials, testing, manufacturing, and other services. These contracts generally provide for termination upon notice and are cancellable without significant penalty or payment, and do not contain any minimum purchase commitments.
Guarantees and Indemnifications
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with all members of the Board of Directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any
17
Table of Contents
material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2026 and December 31, 2025.
Other Commitments
In addition to the Company’s obligation to make potential royalty payments under the BCM First Agreement and BCM Second Agreement (both as discussed and defined in Note 13, License Agreements), the Company is also obligated to pay royalties to each of its founders in an amount equal to
13.License Agreements
In July 2012, Stem Med Limited Partnership (StemMed) entered into a license agreement (the BCM First Agreement) with Baylor College of Medicine (BCM) for the exclusive, worldwide, sublicensable license to certain patents and patent applications related to STAT3 inhibitors in oncology and certain non-oncology indications (the BCM Patent Rights), which are referred to together with certain cell lines, biological materials, compounds, know-how and technologies as the BCM Technology, in all fields of use. Under the license for the BCM First Agreement, the Company is permitted to make, have made, use, market, sell, offer to sell, lease and import products, processes or services that incorporate, utilize, or are made with the use of the BCM Patent Rights or BCM Technology, which is referred to together as the BCM1 Licensed Products, in all fields of use.
In June 2015, StemMed entered into a second license agreement with BCM (the BCM Second Agreement), which is referred to together with the BCM First Agreement as the BCM License Agreements, for the exclusive, worldwide, sublicensable license to certain patents and patent applications co-owned by BCM and the National Institutes of Health (NIH) related to methods and compositions for the use of STAT3 inhibitors in certain conditions like anaphylaxis (the Licensed Patent Rights). Under the license for the Second BCM Agreement, the Company is permitted to make, have made, use, market, sell, offer to sell, lease and import products, processes or services that incorporate, utilize or are made with the use of the Licensed Patent Rights (the BCM2 Licensed Products), in all fields of use. In April 2026, the Company terminated the BCM Second Agreement related to conditions like anaphylaxis, effective immediately. The Company determined that this termination was not material because the Company has not been and will not be pursuing development in conditions like anaphylaxis.
StemMed assigned the BCM First Agreement and the BCM Second Agreement to the Company in connection with the transfer of all or substantially all of the assets and businesses to which the BCM License Agreements relate to in January and February 2018.
In accordance with BCM License Agreements, and in consideration for the rights and licenses granted to the Company, the Company agreed to pay BCM the following:
a. | Annual maintenance fees, ranging from $ |
b. | Milestone payments, up to a low-seven digit figure in the aggregate. |
c. | Royalty fees, set at a low single-digit percentage of net sales of any BCM1 Licensed Products or BCM2 Licensed Products. |
Milestones include new drug filings, clinical trial stages, and New Drug Application approval by the FDA.
18
Table of Contents
As of June 30, 2026, the Company accrued $
14.Segment Reporting
The Company has
The Company’s Chief Operating Decision Maker (CODM), its Chief Executive Officer and Chief Financial Officer, manages the Company’s operations at a company-wide level for the purpose of allocating resources. The key measure of segment profit or loss that the CODM uses to allocate resources and assess financial performance is the Company’s net (loss) income, which is utilized to evaluate the progress of its research and development programs and other expense categories. The CODM makes decisions using this information on a company-wide basis.
The table below shows a reconciliation of the Company’s net (loss) income, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net (loss) income in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):
| | | | | | | | | | | | |
| | For the Three Months Ended | | For the Six Months Ended | ||||||||
| | 2026 | | 2025 | | 2026 | | 2025 | ||||
Direct research and development expenses by program: |
| | |
| | |
| | |
| | |
TTI-101: |
| | |
| | |
| | |
| | |
HCC | | $ | | | $ | | | $ | | | $ | |
IPF | |
| | |
| | |
| | |
| |
mBC | |
| ( | |
| ( | |
| ( | |
| ( |
Pre-clinical, CMC, and other (unallocated) (1) | |
| | |
| | |
| | |
| |
TTI-109 | |
| | |
| | |
| | |
| |
Unallocated research and development expense: | |
| | |
| | |
| | |
| |
Personnel costs | |
| | |
| | |
| | |
| |
Consultant fees and other costs (2) | |
| | |
| | |
| | |
| |
General and administrative expense: | |
| | |
| | |
| | |
| |
Personnel costs | |
| | |
| | |
| | |
| |
Other general and administrative expenses (3) | |
| | |
| | |
| | |
| |
Interest income | |
| ( | |
| ( | |
| ( | |
| ( |
Other income, net | |
| — | |
| ( | |
| — | |
| ( |
Net (loss) income | | $ | ( | | $ | | | $ | ( | | $ | ( |
(1) | Pre-clinical, chemistry, manufacturing and control (CMC), and other (unallocated) costs include preclinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program. |
(2) | Consultant fees and other costs include expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function. |
(3) | Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses. |
Assets provided to the CODM are consistent with those reported on the condensed consolidated balance sheets. The Company does not have intra-entity sales or transfers.
15.Subsequent Events
On July 17, 2026, the Company filed a new sales agreement prospectus supplement (New Sales Agreement Prospectus Supplement) included in the Registration Statement. The New Sales Agreement Prospectus Supplement reflects the offering, issuance and sale of up to approximately $
19
Table of Contents
The Company is subject to General Instruction I.B.6 of Form S-3 which limits the amounts that the Company may sell under the Registration Statement of which the New Sales Agreement Prospectus Supplement forms a part. Subsequent to June 30, 2026, the Company sold an aggregate of
From the date of the New Sales Agreement Prospectus Supplement through August 11, 2026, the Company sold an aggregate of
20
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report. In addition to historical financial information, the following discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Quarterly Report.
On December 17, 2024, the Delaware corporation formerly known as Tvardi Therapeutics, Inc. (Legacy Tvardi) entered into an agreement and plan of merger and reorganization (the Merger Agreement) with Cara Therapeutics, Inc. (Cara), and CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of Cara (Merger Sub), pursuant to which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of Cara (such transaction, the Merger). Upon the closing of the Merger on April 15, 2025, Cara changed its corporate name to Tvardi Therapeutics, Inc. and Legacy Tvardi’s business continued as the business of the Company.
Unless otherwise indicated or the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section to “Tvardi,” the “Company,” “we,” “us,” “our” and other similar terms refer to the business and operations of Legacy Tvardi prior to the Merger and to Tvardi Therapeutics, Inc. and its consolidated subsidiaries following the Merger.
Overview
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing.
Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). We expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 clinical trial in patients with HCC in the fourth quarter of 2026. TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance systemic drug delivery and improve tolerability. We submitted an Investigational New Drug (IND) application for TTI-109 in June 2025 and, following U.S. Food and Drug Administration (FDA) acceptance, initiated a Phase 1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics and bioequivalence to TTI-101. We reported positive topline data from this trial in July 2026. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC50 and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven immune cell populations across Th17, T follicular helper (Tfh) and B cell subsets. Later in July 2026, we announced that we had selected ulcerative colitis (UC) as the initial disease indication for TTI-109. See “— Recent Developments.”
In October 2025, we reported preliminary data from our Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) and concluded that the study did not meet its goals. Subsequently, we conducted additional analyses of a subset of patients who received study drug for 12 weeks. Based on these analyses, which excluded certain patients due to dosing, pharmacokinetic, or clinical factors, treatment with TTI-101 demonstrated greater reductions in certain exploratory measures, including fibrosis and inflammatory markers, compared to placebo — directly recapitulating findings from multiple preclinical models of fibrotic disease and providing human clinical proof of concept for the STAT3 inhibition mechanism. We continue to evaluate these results to inform potential future development decisions.
Since commencing operations in 2017, we have devoted substantially all of our efforts and financial resources to developing our product candidates, organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product candidates, signaling and biology, medicinal chemistry and clinical insights to discover and develop novel therapies for the treatment of
21
Table of Contents
inflammatory and proliferative diseases driven by dysregulated STAT3 signaling. Through the date of this filing, we have historically financed our operations principally through the issuance and sale of our preferred stock and convertible debt. We received $28.3 million from the sale and issuance of our convertible promissory notes (Convertible Notes) in December 2024, which were converted into common stock in April 2025, and $83.4 million from the issuance and sale of our preferred stock and historical convertible debt, which was converted into preferred stock, in 2018 and 2021. We acquired approximately $23.9 million of net assets in connection with our Merger with Cara in April 2025. Additional information regarding the Merger is included in Note 8, Stockholders’ Equity (Deficit), included in the Notes to Condensed Consolidated Financial Statements, included elsewhere within this Quarterly Report.
As of June 30, 2026, we had $15.8 million in cash and cash equivalents. We have incurred net losses since inception. As of June 30, 2026 and December 31, 2025, our accumulated deficit was $123.7 million and $110.5 million, respectively. For the three and six months ended June 30, 2026, we reported net losses of $6.5 million and $13.3 million, respectively. For the three and six months ended June 30, 2025, we reported net income of $4.2 million and net loss of $5.4 million. Our net (loss) income may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical development activities and other research and development activities. Although we generated net income for the three months ended June 30, 2025 as a result of the net changes in fair value of our Convertible Notes (as described below), we expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. Losses are expected to continue as we continue to invest in research and development activities. We evaluated whether there were conditions and events, considered in the aggregate, that are known or reasonably knowable as of the date that these condensed consolidated financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about our ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. See the subsection titled “— Liquidity and Capital Resources” below for further discussion.
We will require additional funding in order to finance operations and complete our ongoing and planned clinical trials. Access to such funding on acceptable terms cannot be assured.
We expect that our expense and capital requirements will increase substantially in connection with our ongoing activities and for the foreseeable future, particularly if we, among other things:
| ● | advance TTI-101, TTI-109 and our other product candidates through clinical development and, if successful, later-stage clinical trials; |
| ● | discover and develop additional product candidates; |
| ● | advance our preclinical development programs into clinical development; |
| ● | experience delays or interruptions to preclinical studies, clinical trials, receipt of services from our third-party service providers on whom we rely, or our supply chain; |
| ● | seek and maintain regulatory approvals for any product candidates that successfully complete clinical trials; |
| ● | commercialize TTI-101, TTI-109, our other product candidates and any future product candidates, if approved; |
| ● | hire additional clinical development, quality control, scientific and management personnel; |
| ● | expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts and operations as a public company; |
| ● | establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; |
| ● | maintain, expand and protect our intellectual property portfolio; |
| ● | invest in or in-license other technologies or product candidates; |
22
Table of Contents
| ● | continue to build out our organization to engage in such activities; and |
| ● | incur additional legal, accounting, investor relations and other general and administrative expenses associated with operating as a public company. |
Given our stage of development, to date we have not had any products approved for sale and have not generated any revenue. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which may not be for several years, if ever. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants or other restrictions limiting our ability to engage in specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities, including our ongoing and planned clinical trials, to reduce costs.
Additionally, we are subject to risks and uncertainties as a result of global business, political and macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, uncertainty with respect to the federal budget and debt ceiling, as well as the potential for future potential government shutdowns related thereto, potential instability in the global banking system, cybersecurity events, the impact of war or military conflict, including regional conflicts around the world, and public health pandemics. Our business, financial condition and results of operations could be materially and adversely affected by further negative impact on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen.
Although, to date, our business has not been materially impacted by these global economic and geopolitical conditions, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such instability could impact our business and results of operations. The extent and duration of these market disruptions, other geopolitical tensions, record inflation, tariffs or otherwise, are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Quarterly Report.
Recent Developments
TTI-109 Phase 1 Clinical Trial Results
In July 2026, we announced Phase 1 results for TTI-109, our next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound’s mechanism of action. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC50 and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh and B cell subsets.
Key findings included:
| ● | Confirmed prodrug conversion and exposure equivalence: Validating its prodrug design, TTI-109 rapidly converted to TTI-101 within two hours and produced nearly identical plasma levels at molar-equivalent doses. |
| ● | Sustained target-level exposure: 21-day repeat dosing showed stable, dose-proportional pharmacokinetics, with TTI-101 concentrations above the STAT3 IC50. |
23
Table of Contents
| ● | Evidence of target engagement: Pharmacodynamic data showed reductions of up to 60% across disease-relevant STAT3-driven immune cell populations including Th17 cells, Tfh and B cell subsets. |
| ● | Improved tolerability vs. TTI-101: Compared with placebo, diarrhea events with TTI-109 were similar in duration, transient and resolved without treatment interruption. Compared with TTI-101 at near-equivalent doses, diarrhea events with TTI-109 were substantially shorter in duration (0.46 vs. 3.35 days). |
We have identified dermatologic and gastrointestinal therapeutic areas with shared STAT3-driven disease biology, specifically the convergence of cytokines, growth factors and Th17 and B cell immune pathways at the STAT3 node. TTI-109 is designed to address both the cellular and humoral components of inflammation and proliferation with a single oral agent. Recent programs in related STAT3-driven indications have validated the underlying biology, but each acts on a single upstream target, while TTI-109 targets STAT3, the downstream node where these pathways converge.
STAT3 sits at the center of the core disease processes in dermatologic and gastrointestinal diseases, including inflammation, proliferation and cellular and humoral dysregulation. Our STAT3 inhibitors have demonstrated biologic activity in these pathways in both preclinical models and in the clinic. In preclinical disease models, our STAT3 inhibitors reduced inflammatory cascades, fibrosis and modulated immune activity. Similarly, in humans, TTI-101 reduced activated STAT3 levels, inflammatory cascades and fibrosis. The TTI-109 healthy volunteer study extended this translational profile, with reductions in STAT3-driven immune cell populations.
Later in July 2026, we announced that we had selected UC as the initial disease indication for TTI-109. Our decision follows our successful Phase 1 healthy volunteer study, in which TTI-109 successfully modulated multiple STAT3-driven immune cell populations, including Th17, Tfh and B cells. These same cell types are known to expand with UC disease severity and infiltrate the inflamed colon.
Further analysis of immune cell populations across the active dose range elucidated:
| ● | Broad suppression of pathogenic Th17-associated immune populations, including up to 76% reduction in subsets associated with mucosal destruction and treatment-refractory UC |
| ● | The Tfh immune populations that drive mucosal B cell responses were reduced up to 43% in Tfh subsets associated with disease UC activity |
| ● | Suppression extended to B cell (humoral) immunity, including up to 71% decline in subsets associated with colonic inflammation |
STAT 3 sits at the center of the three interconnected processes that drive UC: immune dysregulation, chronic inflammation and the tissue remodeling that leads to fibrosis, positioning it as a single, convergent therapeutic target for a disease with multiple underlying drivers. These findings are further supported by published clinical studies linking reductions in activated STAT3 with higher rates of clinical remission across multiple UC therapeutic classes.
UC is a large and underserved market. More than 1.25 million patients are diagnosed with UC in the United States, representing an addressable market of approximately $3 billion in the U.S. and $9 billion globally. Currently approved therapies, including anti-TNF, anti-integrin, anti-IL-12/23, S1P and JAK inhibitors, achieve placebo-adjusted clinical remission rates below 30%, and most are administered parenterally. Additionally, JAK inhibitors carry a black box warning for major adverse cardiovascular events, mortality, thrombosis, serious infections and malignancy.
By contrast, TTI-109, an oral small molecule, is designed to inhibit STAT3 directly, addressing the inflammation, immune dysregulation and proliferation that single-pathway therapies leave unresolved. Across more than 400 subjects dosed to date with our STAT3 inhibitors demonstrated a differentiated safety profile from JAK inhibitors. TTI-109 is administered orally without a loading dose, and in preclinical models of UC, achieved more than eight-fold greater drug concentration in target tissue relative to plasma.
Our ability to initiate these programs is subject to clearance of an IND application and the availability of additional funding.
24
Table of Contents
License Agreements
In July 2012 and June 2015, Stem Med Limited Partnership (StemMed) entered into license agreements with Baylor College of Medicine (BCM) referred to herein as the BCM First Agreement and BCM Second Agreement, respectively. StemMed assigned the BCM First Agreement and BCM Second Agreement to us in connection with the transfer of all or substantially all of the assets and businesses to which BCM First Agreement and BCM Second Agreement relate in January 2018 and February 2018, respectively. Under both the BCM First Agreement and BCM Second Agreement, we obtained exclusive, worldwide, sublicense licenses under certain of BCM’s patents and patent applications and additionally in the case of the BCM First Agreement, certain BCM technology. Under these licenses, we are permitted to make, have made, use, market, sell, offer to sell, lease and import products, processes or services that incorporate, utilize or are made with the use such patents and patent applications or technologies (respectively, the BCM1 Licensed Products and BCM2 Licensed Products) in all fields of use. In April 2026, we terminated the BCM Second Agreement related to conditions like anaphylaxis, effective immediately.
The licenses, patents and patent applications and technologies applicable to the BCM First Agreement and BCM Second Agreement are further discussed below.
First License Agreement with Baylor College of Medicine
Under the BCM First Agreement, we obtained an exclusive, worldwide, sublicensable license under BCM’s rights to certain patents and patent applications related to STAT3 inhibitors in oncology and certain non-oncology indications, which we refer to as the BCM Patent Rights, together with certain cell lines, biological materials, compounds, know-how and technologies, which we collectively refer to as the BCM Technology, to make, have made, use, market, sell, offer to sell, lease and import BCM1 Licensed Products, in all fields of use.
Pursuant to the terms of the BCM First Agreement, StemMed owed an initial license fee of $75,000 as consideration for the license rights. Upon the assignment of the agreement to us, we became responsible for the payment of annual maintenance fees on the anniversary of the agreement, which range from $30,000 to $50,000. We are also required to pay BCM royalties in the amount of a low single-digit percent of net sales of BCM1 Licensed Products during the term, which expires, on a country-by-country basis, on the later of (i) the date of expiration of the last-to-expire of the BCM Patent Rights, or, (ii) if no BCM Patent Rights issued in such country, the tenth anniversary of the first commercial sale of the BCM1 Licensed Product in such country. We currently expect the BCM Patent Rights to expire April 18, 2039. Upon the initiation of the Phase 2 clinical trials for two BCM1 Licensed Products, we paid BCM development milestone payments of $250,000 in the aggregate. Upon the achievement of additional specified development and regulatory milestones, we are required to pay BCM one-time milestone payments of up to $2,200,000 in the aggregate for the first BCM1 Licensed Product in an oncology indication and for the first BCM1 Licensed Product in a non-oncology indication to achieve such milestones. Further, in connection with the initiation of the Phase 3 clinical trial, we would expect to incur approximately $400,000 of oncology-related costs and approximately $300,000 of non-oncology-related costs. We are additionally required to pay BCM a tiered low double-digit percentage of sublicensing revenue obtained in connection with any sublicense granted by us under the BCM Patent Rights or BCM Technology.
We may terminate the BCM First Agreement at its convenience following a specified notice period upon advance written notice to BCM. The BCM First Agreement may also be terminated by BCM for our default or failure to perform any of the terms of the BCM First Agreement, following a specified notice and cure period. Additionally, BCM may terminate the BCM First Agreement if we undergo specified bankruptcy or insolvency events, following the expiration of a specified period. Upon expiration of the term of the BCM First Agreement in a given country, the license grant from BCM to us will be fully-paid and perpetual in such country.
The BCM First Agreement was amended in April 2015 to update the schedule of BCM Patent Rights and description of BCM Technology covered by the license for immaterial consideration. The BCM First Agreement was further amended in August 2019 to amend our diligence and insurance obligations as well as to further update the schedule of BCM Patent Rights.
Under the BCM First Agreement, we accrued $25,000 in annual maintenance fees as of June 30, 2026. As of December 31, 2025, the full amount of $50,000 in annual maintenance fees had already been paid and thus no accrual was needed. No payments for maintenance or milestone fees were made during the three and six months ended June 30,
25
Table of Contents
2026. No royalty fees have been incurred to date. All related license costs are expensed as incurred within research and development on the condensed consolidated statements of operations and comprehensive (loss) income.
Second License Agreement with Baylor College of Medicine
Under the BCM Second Agreement, we obtained an exclusive, worldwide, sublicensable license under certain patents and patent applications co-owned by BCM and the National Institutes of Health (NIH), related to methods and compositions for the use of STAT3 inhibitors in certain conditions like anaphylaxis, which rights we refer to as the Licensed Patent Rights, to make, have made, use, market, sell, offer to sell, lease and import the BCM2 Licensed Products, in all fields of use.
Pursuant to the terms of the BCM Second Agreement, StemMed owed an initial license fee of $5,000 in consideration for the license rights. Upon the assignment of the agreement to us, we became responsible for the payment of maintenance fees on the anniversary of the agreement, which range from $30,000 to $50,000. We are also required to pay BCM royalties in the amount of a low single-digit percent of net sales of BCM2 Licensed Products during the term, which expires, on a country-by-country basis, on the later (i) of the date of expiration of the last to expire of the Licensed Patent Rights, or, (ii) if no Licensed Patent Rights issued in such country, the tenth anniversary of the first commercial sale of the BCM2 Licensed Product in such country. We currently expect the Licensed Patent Rights to expire July 18, 2034. Upon the achievement of additional specified development and regulatory milestones, we are required to pay BCM one-time milestone payments of up to $1,225,000 in the aggregate for the first BCM2 Licensed Product to achieve such milestones. Further, in connection with the initiation of the Phase 3 clinical trial, we would expect to incur approximately $300,000 in costs. We are additionally required to pay BCM a tiered low double-digit percentage of sublicensing revenue obtained in connection with any sublicense granted by us under the Licensed Patent Rights.
We may terminate the BCM Second Agreement at our convenience following a specified notice period upon advance written notice to BCM. The BCM Second Agreement may also be terminated by BCM for our default or failure to perform any of terms of the BCM Second Agreement, following a specified notice and cure period. Additionally, BCM may terminate the BCM Second Agreement if we undergo specified bankruptcy or insolvency events, following the expiration of a specified period. The NIH may terminate its license to BCM if we fail to fulfill certain obligations. Upon expiration of the term of the BCM Second Agreement in a given country, the license grant from BCM to us will be fully paid and perpetual in such country.
The BCM Second Agreement was amended in June 2019 to amend our diligence and insurance obligations. We entered into a second amendment in April 2023 to further amend our diligence obligations and to terminate the obligation to pay annual maintenance fees until the first anniversary of the achievement of certain patent milestones and annually thereafter. In April 2026, we terminated the BCM Second Agreement related to conditions like anaphylaxis, effective immediately.
Under the BCM Second Agreement, no payments were made or incurred during the three and six months ended June 30, 2026 and 2025. No royalty fees have been incurred to date.
Components of Operating Results
Revenue
We have not generated any revenue since our inception and we do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts for TTI-101, TTI-109 or additional product candidates that we may develop in the future are successful and result in marketing approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.
Operating Expenses
Our operating expenses have consisted primarily of research and development expenses and general and administrative costs.
26
Table of Contents
Research and Development Expenses
Our research and development expenses consist primarily of direct and indirect costs incurred in performing clinical and preclinical development activities.
Direct costs include:
| ● | expenses incurred under agreements with consultants and third-party contract research organizations (CROs) that conduct research and development activities on our behalf; |
| ● | costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; and |
| ● | costs associated with license agreements. |
Indirect costs include:
| ● | personnel costs, which includes salaries, benefits, stock-based compensation expense and travel expenses, for personnel engaged in research and development functions; |
| ● | facilities, amortization and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and |
| ● | costs related to compliance with quality and regulatory requirements. |
Pursuant to U.S. GAAP and our internal policies, including our clinical trial accrual policy, we expense all research and development costs in the periods in which they are incurred, including the costs of treatment center start-up activities, patient enrollment, and study reporting. Costs for certain other research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as prepaid or accrued research and development expenses.
The majority of our clinical spending during the three and six months ended June 30, 2026 was on TTI-109, which included costs related to the second arm of the healthy volunteer study, chemistry, manufacturing and control (CMC) costs related to clinical supply, and preclinical studies. Costs for TTI-101 were also incurred for the HCC trial during the three and six months ended June 30, 2026. The majority of our clinical spending during the three and six months ended June 30, 2025 was on TTI-101, for which certain direct research and development costs were tracked by clinical trial. Costs incurred for TTI-109 during the three and six months ended June 30, 2025 were related to CMC costs as well as pre-clinical costs.
We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in the development of TTI-101 and TTI-109, support our ongoing preclinical programs and discover any new product candidates, as well as increase our headcount. In particular, clinical development, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our clinical activities, which are managed by our CROs, and Contract Development and Manufacturing Organizations (CDMOs), to manufacture materials for our product candidates and future commercial products, are much more costly as compared to early-stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our current and future candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each therapeutic candidate’s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to
27
Table of Contents
future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including:
| ● | negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; |
| ● | undesirable product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or therapeutics similar to our product candidates; |
| ● | poor efficacy of our product candidates during clinical trials; |
| ● | delays in submitting IND applications or comparable foreign applications or delays or failure in obtaining the necessary approvals from the FDA or other comparable foreign regulatory authorities to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; |
| ● | conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials; |
| ● | delays in enrolling subjects in clinical trials, including due to operational challenges or competition with other clinical trials; |
| ● | high drop-out rates or screening failures of subjects from clinical trials; |
| ● | inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials; |
| ● | greater than anticipated clinical trial costs; |
| ● | inability to compete with other therapies; |
| ● | failure to secure or maintain orphan designation in some jurisdictions; |
| ● | unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; |
| ● | failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; |
| ● | delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or |
| ● | varying interpretations of data by the FDA and other comparable foreign regulatory authorities. |
A change in the outcome of any of these variables with respect to the development of any of our product candidates or potential future product candidates could mean a significant change in the costs and timing associated with the development of that product candidate or potential future product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate would be required for the completion of clinical development of a product candidate or potential future product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We
28
Table of Contents
may never obtain regulatory approval for any of our product candidates, and, even if we do, drug commercialization takes several years and millions of dollars in development costs.
General and Administrative Expenses
General and administrative (G&A) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. G&A expenses also include outside professional services, such as legal, audit and accounting services, insurance costs and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
We expect our G&A expenses to increase over the next several years as we continue our research and development activities, prepare for potential commercialization of our current and future product candidates, as well as expand our operations and continue operating as a public company following the Merger. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with listing rules and Securities and Exchange Commission (SEC) requirements, director and officer insurance premiums and investor relations costs associated with being a public company.
Interest Income
Interest income for the three and six months ended June 30, 2026 and 2025 consisted of interest earned on our cash and cash equivalents as well as interest earned on short-term investments and the accretion of the discount of our short-term investments.
Other Income, Net
Other income, net consists of the net changes in fair value of our Convertible Notes, for which we elected the fair value option, as well as interest accrued on the Convertible Notes. The Convertible Notes converted into our common stock upon the closing of the Merger in April 2025. As a result, there were no Convertible Notes outstanding during the three and six months ended June 30, 2026. See Note 11, Net (Loss) Income Per Share, included in the Notes to Condensed Consolidated Financial Statements, included elsewhere within this Quarterly Report for further discussion of our Convertible Notes.
Income Taxes
For the three and six months ended June 30, 2026 and 2025, there was no current or deferred income tax expense or benefit due to our current year losses and full valuation allowance. As of June 30, 2026, we evaluated all available evidence and concluded that a valuation allowance was still required against our net deferred tax assets because it is more likely than not they will not be realized in the foreseeable future. As a result, our effective tax rate for each of the periods presented differs from the U.S. federal statutory rate primarily due to recurring operating losses and the full valuation allowance against deferred tax assets.
29
Table of Contents
Results of Operations
Comparison of the Three and Six Months Ended June 30, 2026 and 2025
The following table sets forth our results of operations for the three and six months ended June 30, 2026 and 2025 (in thousands, except percentages):
| | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | | |
| Six Months Ended | | | | | |
| ||||||||
| | June 30, | | Change |
| June 30, | | Change |
| ||||||||||||||
| | 2026 | | 2025 | | Amount | | Percent |
| 2026 | | 2025 | | Amount | | Percent |
| ||||||
Operating expenses: |
| | |
| | |
| | |
| | | | |
| | |
| | |
| | |
Research and development | | $ | 4,002 | | $ | 5,806 | | $ | (1,804) |
| (31.1) | % | $ | 8,913 | | $ | 8,917 | | $ | (4) |
| (0.0) | % |
General and administrative | |
| 2,627 | |
| 3,063 | |
| (436) |
| (14.2) | % |
| 4,767 | |
| 4,306 | |
| 461 |
| 10.7 | % |
Total operating expenses | |
| 6,629 | |
| 8,869 | |
| (2,240) |
| (25.3) | % |
| 13,680 | |
| 13,223 | |
| 457 |
| 3.5 | % |
Loss from operations | |
| (6,629) | |
| (8,869) | |
| 2,240 |
| (25.3) | % |
| (13,680) | |
| (13,223) | |
| (457) |
| 3.5 | % |
Interest income | |
| 172 | |
| 377 | |
| (205) |
| (54.4) | % |
| 419 | |
| 652 | |
| (233) |
| (35.7) | % |
Other income, net | |
| — | |
| 12,659 | |
| (12,659) |
| (100.0) | % |
| — | |
| 7,159 | |
| (7,159) |
| (100.0) | % |
Net (loss) income | | $ | (6,457) | | $ | 4,167 | | $ | (10,624) |
| (255.0) | % | $ | (13,261) | | $ | (5,412) | | $ | (7,849) |
| 145.0 | % |
Research and Development Expenses
Research and development expenses for the three and six months ended June 30, 2026 and 2025 were comprised of the following (in thousands, except percentages):
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | | |
| | Six Months Ended | | | | | |
| ||||||||
| | June 30, | | Change |
| | June 30, | | Change |
| ||||||||||||||
| | 2026 | | 2025 | | Amount | | Percent |
| | 2026 | | 2025 | | Amount | | Percent |
| ||||||
Direct research and development expenses by program: |
| | |
| | |
| | |
| | | | | |
| | |
| | |
| | |
TTI-101: |
| | |
| | |
| | |
| | | | | |
| | |
| | |
| | |
HCC | | $ | 1,118 | | $ | 967 | | $ | 151 |
| 15.6 | % | | $ | 1,818 | | $ | 1,404 | | $ | 414 |
| 29.5 | % |
IPF | |
| 137 | |
| 2,830 | |
| (2,693) |
| (95.2) | % | |
| 137 | |
| 3,863 | |
| (3,726) |
| (96.5) | % |
mBC | |
| (5) | |
| (268) | |
| 263 |
| (98.1) | % | |
| (5) | |
| (268) | |
| 263 |
| (98.1) | % |
Pre-clinical, CMC, and other (unallocated) | |
| 105 | |
| 140 | |
| (35) |
| (25.0) | % | |
| 192 | |
| 315 | |
| (123) |
| (39.0) | % |
TTI-109 | |
| 1,362 | |
| 822 | |
| 540 |
| 65.7 | % | |
| 4,264 | |
| 1,180 | |
| 3,084 |
| 261.4 | % |
Unallocated research and development expense: | |
| | |
| | |
| |
| | | |
| | |
| | |
| |
| | |
Personnel costs (including stock-based compensation) | |
| 926 | |
| 917 | |
| 9 |
| 1.0 | % | |
| 1,930 | |
| 1,775 | |
| 155 |
| 8.7 | % |
Consultant fees and other costs | |
| 359 | |
| 398 | |
| (39) |
| (9.8) | % | |
| 577 | |
| 648 | |
| (71) |
| (11.0) | % |
Total research and development expenses | | $ | 4,002 | | $ | 5,806 | | $ | (1,804) |
| (31.1) | % | | $ | 8,913 | | $ | 8,917 | | $ | (4) |
| (0.0) | % |
Research and development expenses were $4.0 million for the three months ended June 30, 2026, compared to $5.8 million for the three months ended June 30, 2025. The decrease of $1.8 million was primarily driven by a net decrease in costs associated with our product candidate TTI-101, which included a decrease of $2.7 million related to our IPF trial and an increase of $0.2 million related to our HCC trial, partially offset by an increase of $0.5 million in costs related to our product candidate TTI-109, which included costs associated with the second arm of the healthy volunteer study, CMC costs related to clinical supply, and preclinical studies. We incurred $2.8 million in costs related to our IPF trial during the three months ended June 30, 2025 as we were still enrolling patients in this trial. Costs decreased substantially to $0.1 million during the three months ended June 30, 2026 given all patients had been enrolled in our IPF trial prior to the current period; however, final costs are expected to be incurred later in fiscal 2026. The increase in costs related to our HCC trial was primarily due to changes in trial costs, partially offset by a lower number of patients treated.
30
Table of Contents
Research and development expenses were $8.9 million for the six months ended June 30, 2026, which remained substantially consistent with the six months ended June 30, 2025. The minimal decrease was primarily driven by a decrease of $3.7 million related to our IPF trial, partially offset by an increase of $0.4 million related to our HCC trial and an increase of $3.1 million in costs related to our product candidate TTI-109, which included costs associated with the second arm of the healthy volunteer study, CMC costs related to clinical supply, and preclinical studies. We incurred $3.9 million in costs related to our IPF trial during the six months ended June 30, 2025 as we were still enrolling patients in this trial. Costs decreased substantially to $0.1 million during the six months ended June 30, 2026 given all patients had been enrolled prior to the current period; however, final costs are expected to be incurred later in fiscal 2026. The increase in costs related to our HCC trial was primarily due to changes in trial costs, partially offset by a lower number of patients treated.
The increase in personnel costs of $0.2 million was primarily related to an increase in stock-based compensation expense related to additional stock options granted after the first quarter of 2025 through the second quarter of 2026.
General and Administrative Expenses
G&A expenses for the three and six months ended June 30, 2026 and 2025 were comprised of the following (in thousands, except percentages):
| | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | | |
| Six Months Ended | | | | | |
| ||||||||
| | June 30, | | Change |
| June 30, | | Change |
| ||||||||||||||
| | 2026 | | 2025 | | Amount | | Percent | | 2026 | | 2025 | | Amount | | Percent |
| ||||||
Personnel costs |
| $ | 933 |
| $ | 1,038 |
| $ | (105) |
| (10.1) | % | $ | 1,865 |
| $ | 1,647 |
| $ | 218 |
| 13.2 | % |
Professional fees | | | 1,436 | | | 1,628 | | | (192) |
| (11.8) | % | | 2,246 | | | 2,130 | | | 116 |
| 5.4 | % |
Insurance costs | |
| 168 | |
| 151 | |
| 17 |
| 11.3 | % |
| 340 | |
| 165 | |
| 175 |
| 106.1 | % |
Other costs | |
| 90 | |
| 246 | |
| (156) |
| (63.4) | % |
| 316 | |
| 364 | |
| (48) |
| (13.2) | % |
Total general and administrative expenses | | $ | 2,627 | | $ | 3,063 | | $ | (436) |
| (14.2) | % | $ | 4,767 | | $ | 4,306 | | $ | 461 |
| 10.7 | % |
G&A expenses were $2.6 million for the three months ended June 30, 2026, compared to $3.1 million for the three months ended June 30, 2025. The decrease of approximately $0.4 million was primarily driven by a decrease in professional fees. The decrease in professional fees was primarily attributable to higher accounting and consulting fees during the three months ended June 30, 2025 due to the Merger in April 2025, partially offset by increased legal and investor relations fees incurred as a result of the Merger and subsequent filings as a public company. The remaining decrease was primarily attributable to decreases in personnel and other costs.
G&A expenses were $4.8 million for the six months ended June 30, 2026, compared to $4.3 million for the six months ended June 30, 2025. The increase of approximately $0.5 million was primarily driven by increases in personnel costs of $0.2 million and insurance costs of $0.2 million. The increase in personnel costs was primarily attributable to increases in stock-based compensation related to additional stock options granted after the first quarter of 2025 through the second quarter of 2026 and additional headcount. The increase in insurance costs was primarily attributable to higher director and officer insurance premiums. The remaining increase was primarily attributable to increases in professional fees due to increased legal and investor relations fees incurred as a result of the Merger and subsequent filings as a public company, partially offset by higher accounting and consulting fees during the six months ended June 30, 2025 due to the Merger in April 2025.
Interest Income
Interest income was $0.2 million for the three months ended June 30, 2026, compared to $0.4 million for the three months ended June 30, 2025. The $0.2 million of interest income for the three months ended June 30, 2026 primarily includes interest earned on our cash and cash equivalents. The $0.4 million of interest income for the three months ended June 30, 2025 included $0.1 million of interest earned on our cash and cash equivalents and $0.3
31
Table of Contents
million of interest from our short-term investments, as well as the accretion of the discount on our short-term investments.
Interest income was $0.4 million for the six months ended June 30, 2026, compared to $0.7 million for the six months ended June 30, 2025. The $0.4 million of interest income for the six months ended June 30, 2026 includes $0.3 million of interest earned on our cash and cash equivalents and $0.1 million of interest from our short-term investments, as well as the accretion of the discount on our short-term investments. The $0.7 million of interest income for the six months ended June 30, 2025 included $0.3 million of interest earned on our cash and cash equivalents and $0.4 million of interest from our short-term investments, as well as the accretion of the discount on our short-term investments.
Other Income, Net
For the three and six months ended June 30, 2026, there was no other income, net recorded within the condensed consolidated statements of operations and comprehensive (loss) income, as the Convertible Notes were fully converted during the second quarter of 2025, and there was no remeasurement gain or loss recorded for the three and six months ended June 30, 2026.
For the three months ended June 30, 2025, other income, net of $12.7 million was primarily attributable to a $12.8 million remeasurement gain on our Convertible Notes, for which we elected the fair value option, partially offset by $0.1 million in interest accrued on the Convertible Notes during the three months ended June 30, 2025. At the time of conversion, the fair value of the Convertible Notes was $23.1 million, calculated as 1,265,757 shares of common stock at the closing market trading price on April 16, 2025. The $12.8 million change in fair value was calculated by comparing the $23.1 million at the time of conversion to the $35.9 million recorded value of the Convertible Notes immediately prior to the conversion date.
For the six months ended June 30, 2025, other income, net of $7.2 million was primarily attributable to the $12.8 million remeasurement gain on our Convertible Notes recorded during the three months ended June 30, 2025, partially offset by a $4.9 million remeasurement loss recorded during the first quarter of 2025, as well as $0.7 million in interest accrued on the Convertible Notes during the six months ended June 30, 2025.
Liquidity and Capital Resources
Sources of Liquidity
Since inception, we have not generated any revenue from product sales or any other sources and have incurred significant operating losses. We have not yet commercialized any products and do not expect to generate revenue from sales of any product candidates for several years, if ever. To date, we have financed our operations primarily through the (i) issuance and sale of our Convertible Notes in December 2024 for gross proceeds of $28.3 million (ii) the issuance and sale of preferred stock and historical convertible debt (which converted into preferred stock in 2018 and 2021) for total gross proceeds of $83.4 million, and (iii) our Merger with Cara in which we acquired approximately $23.9 million of net assets in April 2025. To date, we have devoted substantially all of our efforts and financial resources to developing our product candidates, organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product candidates, signaling and biology, medicinal chemistry and clinical insights to discover and develop novel therapies for the treatment of inflammatory and proliferative diseases driven by dysregulated STAT3 signaling. As of June 30, 2026, we had $15.8 million in cash and cash equivalents.
On May 1, 2026, we filed a shelf registration statement on Form S-3 (the Registration Statement) which permits the offering, issuance and sale of common stock, preferred stock, debt securities and warrants having an aggregate offering price of up to $200.0 million in one or more offerings and in any combination of the foregoing. The Registration Statement contains two prospectuses, a base prospectus and an at-the-market offering prospectus (the Original Sales Agreement Prospectus) that covered the offering, issuance and sale of up to $12.5 million of common stock pursuant to a Capital on Demand Sales Agreement (the Sales Agreement), dated as of May 1, 2026 by and between us and JonesTrading Institutional Services LLC acting as sales agent (the ATM Facility). The Registration Statement was
32
Table of Contents
declared effective by the SEC on May 12, 2026. As of June 30, 2026, no securities had been issued under the Registration Statement, including the ATM Facility.
On July 17, 2026, we filed a new sales agreement prospectus supplement (New Sales Agreement Prospectus Supplement) included in the Registration Statement. The New Sales Agreement Prospectus Supplement reflects the offering, issuance and sale of up to approximately $9.7 million of common stock, in addition to any amounts previously sold by us.
We are subject to General Instruction I.B.6 of Form S-3 which limits the amounts that we may sell under the Registration Statement of which the New Sales Agreement Prospectus Supplement forms a part. Subsequent to June 30, 2026, we sold an aggregate of 3,110,769 shares of common stock for an aggregate offering price of approximately $11.0 million in gross proceeds under the Original Sales Agreement Prospectus. No additional common stock will be sold under the Original Sales Agreement Prospectus following the date of the New Sales Agreement Prospectus Supplement.
From the date of the New Sales Agreement Prospectus Supplement through August 11, 2026, we sold an aggregate of 846,830 shares of common stock for an aggregate price of $2.3 million in gross proceeds under the New Sales Agreement Prospectus Supplement.
Funding Requirements
Our primary uses of cash are to fund our operations, which consist primarily of research and development costs related to the development of our product candidates, and, to a lesser extent, G&A costs. We have incurred significant operating losses since our inception, and as of June 30, 2026, had an accumulated deficit of $123.7 million. Management has determined that its present capital resources as of June 30, 2026 will not be sufficient to fund its planned operations for at least one year from the issuance date of the unaudited condensed consolidated financial statements, included elsewhere in this Quarterly Report, which raises substantial doubt as to our ability to continue as a going concern. We plan to seek additional funding through equity offerings, including through our ATM Facility, or debt financings, credit or loan facilities, strategic alliances and licensing arrangements. However, there can be no assurance that such funding will be available to us, will be obtained on terms favorable to us, or will provide us with sufficient funds to meet our objectives.
We anticipate that we will continue to incur significant and potentially increasing expenses for the foreseeable future as we continue to advance our product candidates, expand our corporate infrastructure, including the costs associated with being a public company following the Merger, further our research and development initiatives for our product candidates and incur costs associated with the potential commercialization of our product candidates, if approved. We are subject to all of the risks typically related to the development of new drug candidates, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants or other restrictions limiting our ability to engage in specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.
Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements.
Our future funding requirements will depend on many factors, including, but not limited to:
| ● | the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our potential future product candidates; |
| ● | the clinical development plans we establish for our product candidates; |
33
Table of Contents
| ● | the timelines of our clinical trials and the overall costs to conduct and complete the clinical trials, including any increased costs due to disruptions caused by marketplace conditions, including the effects of health epidemics, or other geopolitical and macroeconomic conditions; |
| ● | the cost and capital commitments required for manufacturing our product candidates at clinical and, if approved, commercial scales; |
| ● | the number and characteristics of product candidates that we develop; |
| ● | the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities; |
| ● | whether we are able to enter into future collaboration agreements and the terms of any such agreements; |
| ● | the ability to achieve and timing of achieving a favorable pricing and reimbursement decision by the pricing authorities in the markets of interest; |
| ● | the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights, including patent infringement actions brought by third parties against us or our product candidates; |
| ● | the effect of competing technological and market developments; |
| ● | the cost and timing of completion of commercial-scale outsourced manufacturing activities; and |
| ● | the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. |
A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. See the section titled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 31, 2026, for additional risks associated with our substantial capital requirements.
Cash Flows
The following table summarizes our cash flows for the periods indicated (in thousands):
| | | | | | | |
| | Six Months Ended |
| ||||
| | June 30, | | ||||
| | 2026 | | 2025 |
| ||
Net cash used in operating activities | | $ | (15,087) | | $ | (13,557) | |
Net cash provided by (used in) investing activities | |
| 10,118 | |
| (20,433) | |
Net cash provided by financing activities | |
| — | |
| 23,024 | |
Net decrease in cash and cash equivalents | | $ | (4,969) | | $ | (10,966) | |
Operating Activities
Net cash used in operating activities was $15.1 million for the six months ended June 30, 2026, reflecting a net loss of $13.3 million and net changes in operating assets and liabilities of $2.6 million, partially offset by non-cash changes of $0.7 million. The net changes in operating assets and liabilities were primarily driven by a $1.9 million decrease in accounts payable and accrued expenses, driven by the timing of invoices and payments, and a $0.6 million increase in prepaid expenses and other current assets, attributable to timing of payments for pre-clinical activities and prepaid insurance. The changes in non-cash expenses were primarily driven by $0.7 million related to stock-based compensation expense.
34
Table of Contents
Net cash used in operating activities was $13.6 million for the six months ended June 30, 2025, reflecting a net loss of $5.4 million, non-cash changes of $6.5 million, and changes in operating assets and liabilities of $1.6 million. The changes of $6.5 million in non-cash expenses were primarily driven by $7.8 million related to the net change in fair value of our Convertible Notes, partially offset by $0.7 million related to stock-based compensation expense and $0.7 million in interest accrued on our Convertible Notes during the six months ended June 30, 2025. The net changes in operating assets and liabilities of $1.6 million were primarily driven by a $1.7 million increase in prepaid expenses and other current assets, attributable to payments for pre-clinical activities and prepaid insurance, partially offset by a $0.1 million increase in accounts payable and accrued expenses, driven by the timing of invoices and payments.
Investing Activities
Net cash provided by investing activities was $10.1 million for the six months ended June 30, 2026, attributable to maturities of short-term investments of $10.1 million.
Net cash used in investing activities was $20.4 million for the six months ended June 30, 2025, attributable to purchases of short-term investments of $31.5 million, partially offset by maturities of short-term investments of $11.1 million.
Financing Activities
There were no cash flows from financing activities for the six months ended June 30, 2026.
The net cash provided by financing activities for the six months ended June 30, 2025 was primarily due to approximately $25.0 million of cash acquired in connection with the Merger and proceeds of $0.4 million from the exercise of stock options, partially offset by payments of $2.4 million related to Merger transaction costs.
Contractual Obligations and Commitments
Lease Obligations
We lease space under one operating lease agreement for corporate office space in Sugar Land, Texas, which expires in August 2027. As of June 30, 2026, we had future operating lease liabilities of $0.1 million, of which $0.1 million is included within operating lease liabilities, current portion on our condensed consolidated balance sheet.
License Agreements
As discussed above, we have license agreements with BCM for exclusive use of patent rights of TTI-101. The license agreements contain terms for annual maintenance fees, milestone payments and net revenue royalties. Annual maintenance fees range from $30,000 to $50,000 per year, per license. Potential milestone payments are up to $1,225,000 in the aggregate per license. Milestones include new drug filings, clinical trial stages, and NDA approval by the FDA. We are obligated to pay BCM royalties in the amount of a low single-digit percent of net sales of BCM1 Licensed Products or BCM2 Licensed Products during the term, which expire, on a country-by-country basis, on the later of (i) the date of expiration of BCM Patent Rights or Licensed Patent Rights, whichever is the last to expire, or, (ii) if no BCM Patent Rights or Licensed Patent Rights are issued in such country, the tenth anniversary the first commercial sale of the BCM1 Licensed Products or BCM2 Licensed Products in such country. License fees are expensed as incurred within research and development within our condensed consolidated statements of operations and comprehensive (loss) income. Under the BCM First Agreement, we accrued $25,000 in annual maintenance fees as of June 30, 2026. As of December 31, 2025, the full amount of $50,000 in annual maintenance fees had already been paid and thus no accrual was needed. No payments for maintenance or milestone fees were made during the three and six months ended June 30, 2026. No royalty fees have been incurred to date. In April 2026, we terminated the BCM Second Agreement related to conditions like anaphylaxis, effective immediately.
Other Capital Requirements and Additional Royalty Obligations
We enter into agreements in the normal course of business with various third-party providers for the provision of research and development services, which include preclinical studies and clinical trial services with CROs and the
35
Table of Contents
manufacturing of product candidates for use in our preclinical studies and clinical trials with CDMOs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. These obligations and commitments are not presented separately.
In addition to our obligation to make potential royalty payments under the BCM First Agreement and BCM Second Agreement discussed above, pursuant to our founder restricted stock purchase agreements with each of our founders, David J. Tweardy, M.D. and Ron DePinho, M.D., we are also obligated to pay royalties to each such founder in an amount equal to 1% each on the worldwide net sales of TTI-101 and any derivative formulations (a Royalty Bearing Product). These royalty obligations last, on a country-by-country basis, for the later of (i) the date on which the sale of Royalty Bearing Product is no longer covered by a Covered Patent (as defined below) in such country, or (ii) 15 years after the first commercial sale of Royalty Bearing Product in such country. The timing of when our royalty payments will actually be made is uncertain as the payments are contingent upon future activities, including the successful development, regulatory approval and commercialization of Royalty Bearing Product. A Covered Patent means, subject to certain customary exceptions, an issued patent that is owned by us or an affiliate, or for which all rights to develop and commercialize pharmaceutical products for the treatment of any human disorder, are exclusively licensed to us or an affiliate by the owner of such patent, with our right or our affiliate’s right to grant sublicenses.
Critical Accounting Estimates
Our unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the unaudited condensed consolidated financial statements and related disclosures requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses in our unaudited condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management evaluates estimates and assumptions on a periodic basis. Our actual results may differ from these estimates.
Our significant accounting policies are described in more detail in Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 31, 2026.
Recently Issued and Adopted Accounting Pronouncements
We are currently evaluating whether any recently issued accounting pronouncements will have a material effect on our financial position, results of operations or cash flows. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements, Summary of Significant Accounting Policies, in this Quarterly Report, for a full description of accounting pronouncements recently adopted, and issued but not yet adopted, if applicable.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our quantitative and qualitative disclosures about market risk from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 31, 2026. Accordingly, the information required by this Item is incorporated herein by reference to Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Form 10-K.
36
Table of Contents
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. Pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026. See below “Material Weaknesses in Internal Control Over Financial Reporting”.
Based on our evaluation, our principal executive officer and principal financial officer have concluded that, as of June 30, 2026, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of material weaknesses that existed in our internal control over financial reporting as described below.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Controls and Procedures
Management, including our principal executive officer and principal financial officer, recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Because of the inherent limitations of the effectiveness of all control systems, no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within Tvardi have been detected.
Material Weaknesses in Internal Control Over Financial Reporting
In connection with the preparation of our consolidated financial statements for the year ended December 31, 2025, material weaknesses were identified in the design and operating effectiveness of our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.
37
Table of Contents
We did not design or maintain an effective control environment and lacked a sufficient number of professionals to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives. The lack of sufficient number of finance and accounting professionals contributed to the inadequate design and inability to maintain effective controls over the segregation of duties.
We have further identified material weaknesses in our internal control over financial reporting which relate to: (a) the lack of a formalized risk assessment process; (b) inadequate review of financial statements and disclosures; (c) inadequate review of the prepaid and accrued research and development expenses related to the CRO; and (d) the lack of formal monitoring activities related to the evaluation of internal controls.
Status of Remediation of Material Weaknesses
To remediate the material weaknesses, we have begun a formal risk assessment process to identify control gaps and design new procedures and controls to remediate the identified material weaknesses. We are also establishing a monitoring program to evaluate the presence and functioning of internal controls. We have added additional experienced accounting and financial reporting personnel and resources and are formalizing the design and implementation of internal controls over the financial reporting process. The material weaknesses will not be considered remediated until management completes the design and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. The measures we have taken to date, and are continuing to design and implement, may not be sufficient to remediate the material weaknesses we identified or avoid potential future material weaknesses. If the steps we take do not correct these material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our consolidated financial statements would not be prevented or detected on a timely basis.
During the fiscal year 2026, management will test and evaluate the related internal controls to ascertain whether they are designed and operating effectively to provide reasonable assurance that they will prevent or detect a material error in the consolidated financial statements.
38
Table of Contents
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
On March 6, 2026, Shaheen Wirk, Palkon Holdings, LLC, and Palkon TT Holdings, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, alleging that we breached the Registration Rights Agreement, dated April 15, 2025, by and among us and the investors party thereto (Registration Rights Agreement) by failing to timely cause a resale registration statement to be declared effective. Such right to an effective resale registration statement had been waived by a majority of the holders of the registrable securities, as defined in the Registration Rights Agreement.
We are, and from time to time, we may be subject to legal proceedings and claims arising in the ordinary course of our business. We are not currently a party or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. The results of any future legal proceedings or claims cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, and other factors.
Item 1A. Risk Factors
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and growth prospects. In such an event, the market price of our common stock could decline. In addition to the other information in this Quarterly Report on Form 10-Q, including the unaudited condensed consolidated financial statements and related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K filed with the SEC on March 31, 2026. We may disclose changes to risk factors or disclose additional risk factors from time to time in our future filings with the SEC. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the three months ended June 30, 2026,
Item 6. Exhibits
| | | | | ||||||
| | | | | | | | Incorporated by Reference | ||
Exhibit | | Description of Exhibit | | Form | | File No. | | Exhibit No. | | Date Filed |
| | | | | | | | | | |
1.1 | | Capital on Demand™ Sales Agreement, dated May 1, 2026, by and between Tvardi Therapeutics, Inc. and JonesTrading Institutional Services LLC. | | S-3 | | 333-295496 | | 1.2 | | May 1, 2026 |
| | | | | | | | | | |
39
Table of Contents
2.1‡ | | Agreement and Plan of Merger and Reorganization, dated as of December 17, 2024, by and among Cara Therapeutics, Inc., CT Convergence Merger Sub, Inc. and Tvardi Therapeutics, Inc. | | 8-K | | 001-36279 | | 2.1 | | December 18, 2024 |
| | | | | | | | | | |
3.1 | | Amended and Restated Certificate of Incorporation. | | 8-K | | 001-36279 | | 3.1 | | February 7, 2014 |
| | | | | | | | | | |
3.2 | | Certificate of Amendment to Amended and Restated Certificate of Incorporation dated June 7, 2024 (First Authorized Shares Amendment). | | 8-K | | 001-36279 | | 3.1 | | June 7, 2024 |
| | | | | | | | | | |
3.3 | | Certificate of Amendment to Amended and Restated Certificate of Incorporation dated December 30, 2024 (First Stock Split Amendment). | | 8-K | | 001-36279 | | 3.1 | | December 30, 2024 |
| | | | | | | | | | |
3.4 | | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Second Stock Split Amendment). | | 8-K | | 001-36279 | | 3.1 | | April 15, 2025 |
| | | | | | | | | | |
3.5 | | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Second Authorized Shares Amendment). | | 8-K | | 001-36279 | | 3.2 | | April 15, 2025 |
| | | | | | | | | | |
3.6 | | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cara Therapeutics, Inc., dated April 15, 2025 (Name Change Amendment). | | 8-K | | 001-36279 | | 3.3 | | April 15, 2025 |
| | | | | | | | | | |
3.7 | | Amended and Restated Bylaws. | | 10-Q | | 001-36279 | | 3.2 | | November 14, 2024 |
| | | | | | | | | | |
31.1† | | Certification of Chief Executive Officer of Tvardi Therapeutics, Inc. pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934. | | | | | | | | |
| | | | | | | | | | |
31.2† | | Certification of Chief Financial Officer of Tvardi Therapeutics, Inc. pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934. | | | | | | | | |
| | | | | | | | | | |
32.1†* | | Certifications of Chief Executive Officer and Chief Financial Officer of Tvardi Therapeutics, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | | | | | | | | |
| | | | | | | | | | |
101.CAL† | | Inline XBRL Taxonomy Extension Calculation Linkbase. | | | | | | | | |
| | | | | | | | | | |
101.INS† | | Inline XBRL Instance Document. | | | | | | | | |
| | | | | | | | | | |
40
Table of Contents
101.LAB† | | Inline XBRL Taxonomy Extension Label Linkbase. | | | | | | | | |
| | | | | | | | | | |
101.PRE† | | Inline XBRL Taxonomy Extension Presentation Linkbase. | | | | | | | | |
| | | | | | | | | | |
101.SCH† | | Inline XBRL Taxonomy Extension Schema Linkbase. | | | | | | | | |
| | | | | | | | | | |
101.DEF† | | Inline XBRL Taxonomy Extension Definition Linkbase Document. | | | | | | | | |
| | | | | | | | | | |
104† | | Cover page interactive data file (formatted as Inline XBRL and contained in Exhibit 101). | | | | | | | | |
† | Filed herewith. |
* | This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. |
‡ | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. |
41
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
| | |
| TVARDI THERAPEUTICS, INC. | |
| | |
Date: August 14, 2026 | By: | /s/ IMRAN ALIBHAI |
| Name: | Imran Alibhai |
| Title: | Chief Executive Officer |
| | (Principal Executive Officer) |
| | |
Date: August 14, 2026 | By: | /s/ DAN CONN |
| Name: | Dan Conn |
| Title: | Chief Financial Officer |
| | (Principal Financial Officer) |
| | |
42